Navigation Links
High-intensity chemotherapy does not improve survival in small cell lung cancer
Date:4/8/2008

Small cell lung cancer (SCLC) patients treated with high-dose chemotherapy did not have better survival rates than those treated with standard doses, according to a randomized controlled trial published online April 8 in the Journal of the National Cancer Institute.

SCLC accounts for nearly 13 percent of lung cancer cases in the United States. Although many patients with SCLC initially respond to chemotherapy, most suffer disease recurrence relatively quickly. Laboratory data suggest that increasing the dose of chemotherapy agents kills SCLC cells that were resistant to standard doses, and thus might improve patient survival.

To test this possibility, Serge Leyvraz, M.D., of the University Hospital in Lausanne, Switzerland, and colleagues enrolled 140 patients with SCLC in a randomized trial that compared high-dose and standard-dose chemotherapy. Both groups were treated with the same chemotherapy agents, ifosfamide, carboplatin, and etoposide (ICE).

The 3-year survival rates in the two arms were similar, with 18 percent of patients in the high-dose arm and 19 percent of patients in the standard-dose arm still alive. Additionally, a similar fraction of patients in both arms showed tumor shrinkage in response to therapy—78 percent in the high-dose arm and 68 percent in the standard-dose arm, which was not a statistically significant difference.

"The approach explored in the present trial succeeded in raising the peak dose, total dose, and dose intensity of ICE by threefold but has clearly been ineffective and highly toxic," the authors write. "As a result, this strategy should be abandoned."

In an accompanying editorial, Paul A. Bunn Jr., M.D., agrees with that assessment and emphasizes that other avenues of therapy should now be explored. "The declining incidence of SCLC and the lack of progress seem to have dampened the enthusiasm of funding agencies and industry for exploring novel therapies. This is indeed unfortunate because SCLC remains a common cancer in both the developed and developing world," Bunn writes.


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. Medicare modernization act did not change chemotherapy as feared
8. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
9. Cancer conflict with chemotherapy treatment
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... More than a ... it is not surprising that bariatric surgery has received increased attention in recent years, ... Of course, when it comes to weight loss, most people are familiar with the ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... ... 26, 2016 , ... Connor Sports, through its Connor Cares initiative, ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame ... in all forms and levels of the game, Connor Sports has committed to a ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse à ... destinés à l,intervention portant sur les membres ... OrbusNeich, entreprise mondiale spécialisée dans ... changer la vie, a élargi son portefeuille ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
Breaking Medicine Technology: